TY - JOUR
KW - Adult
KW - Behavior Therapy/methods
KW - Buprenorphine, Naloxone Drug Combination
KW - Buprenorphine/adverse effects/therapeutic use
KW - Combined Modality Therapy
KW - Drug Combinations
KW - Feasibility Studies
KW - Humans
KW - Male
KW - Middle Aged
KW - Naloxone/adverse effects/therapeutic use
KW - Narcotic Antagonists/adverse effects/therapeutic use
KW - Opiate Substitution Treatment
KW - Opioid-Related Disorders/rehabilitation
KW - Patient Education as Topic/methods
KW - Primary Health Care
KW - Psychotherapy/methods
KW - Social Support
AU - K. Miotto
AU - M. Hillhouse
AU - R. Donovick
AU - J. Cunningham-Rathner
AU - C. Charuvastra
AU - M. Torrington
AU - A. E. Esagoff
AU - W. Ling
A1 - 
AB - Although use of buprenorphine in the treatment of opioid dependence is expected to continue to increase, little is known about the optimal setting for providing the medical and psychosocial care required with buprenorphine pharmacotherapy. OBJECTIVE: This study compared buprenorphine therapy delivered in 3 distinct treatment settings: an opioid treatment program (OTP) offering individual counseling, a group counseling program utilizing the manualized Matrix Model (MMM) of cognitive-behavioral treatment, and a private clinic setting mirroring standard medical management for buprenorphine treatment provided specifically at a psychiatrist's private practice (primary care setting). METHOD: Participants were inducted on buprenorphine and provided with treatment over a 52-week study duration. All participants were scheduled for weekly treatment visits for the first 6 study weeks and 2 sites reduced treatment to monthly visits for dispensing of medication and psychosocial counseling. Outcomes include opioid use, participant retention in treatment, and treatment participation. RESULTS: Participants presenting for treatment at the sites differed only by race/ethnicity and opioid use did not differ by site. Retention differed by treatment site, with the number of participants who stayed in the study until the end of 20 weeks significantly associated with treatment site. The mean number of minutes spent in each individual counseling session also differed by site. Although no difference in opioid use by treatment site was found, results document a significant association between opioid use and buprenorphine dose. DISCUSSION: These results show some differences by treatment site, although the similarity and relative ease in which the sites were able to recruit participants for treatment with buprenorphine, and minor implementation problems reported suggests the feasibility of treatment with buprenorphine across various treatment settings. CONCLUSION: Similar rates of continued opioid use across study sites and few qualitative reports of problems indicates that treatment with buprenorphine and associated psychosocial counseling are safe and relatively easy to implement in a variety of treatment settings.
BT - Journal of addiction medicine
C5 - Opioids & Substance Use
CP - 1
CY - United States
DO - 10.1097/ADM.0b013e318233d621
IS - 1
JF - Journal of addiction medicine
N2 - Although use of buprenorphine in the treatment of opioid dependence is expected to continue to increase, little is known about the optimal setting for providing the medical and psychosocial care required with buprenorphine pharmacotherapy. OBJECTIVE: This study compared buprenorphine therapy delivered in 3 distinct treatment settings: an opioid treatment program (OTP) offering individual counseling, a group counseling program utilizing the manualized Matrix Model (MMM) of cognitive-behavioral treatment, and a private clinic setting mirroring standard medical management for buprenorphine treatment provided specifically at a psychiatrist's private practice (primary care setting). METHOD: Participants were inducted on buprenorphine and provided with treatment over a 52-week study duration. All participants were scheduled for weekly treatment visits for the first 6 study weeks and 2 sites reduced treatment to monthly visits for dispensing of medication and psychosocial counseling. Outcomes include opioid use, participant retention in treatment, and treatment participation. RESULTS: Participants presenting for treatment at the sites differed only by race/ethnicity and opioid use did not differ by site. Retention differed by treatment site, with the number of participants who stayed in the study until the end of 20 weeks significantly associated with treatment site. The mean number of minutes spent in each individual counseling session also differed by site. Although no difference in opioid use by treatment site was found, results document a significant association between opioid use and buprenorphine dose. DISCUSSION: These results show some differences by treatment site, although the similarity and relative ease in which the sites were able to recruit participants for treatment with buprenorphine, and minor implementation problems reported suggests the feasibility of treatment with buprenorphine across various treatment settings. CONCLUSION: Similar rates of continued opioid use across study sites and few qualitative reports of problems indicates that treatment with buprenorphine and associated psychosocial counseling are safe and relatively easy to implement in a variety of treatment settings.
PP - United States
PY - 2012
SN - 1932-0620; 1932-0620
SP - 68
EP - 76
EP - 
T1 - Comparison of buprenorphine treatment for opioid dependence in 3 settings
T2 - Journal of addiction medicine
TI - Comparison of buprenorphine treatment for opioid dependence in 3 settings
U1 - Opioids & Substance Use
U2 - 22105061
U3 - 10.1097/ADM.0b013e318233d621
VL - 6
VO - 1932-0620; 1932-0620
Y1 - 2012
ER -